Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.44
BIIB's Cash-to-Debt is ranked lower than
84% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. BIIB: 0.44 )
Ranked among companies with meaningful Cash-to-Debt only.
BIIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 4.45 Max: No Debt
Current: 0.44
Equity-to-Asset 0.54
BIIB's Equity-to-Asset is ranked lower than
67% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BIIB: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
BIIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.77 Max: 0.96
Current: 0.54
0.48
0.96
Interest Coverage 18.44
BIIB's Interest Coverage is ranked lower than
80% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 18.44 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 18.44  Med: 42.88 Max: 134.66
Current: 18.44
18.44
134.66
Piotroski F-Score: 5
Altman Z-Score: 6.14
Beneish M-Score: -2.48
WACC vs ROIC
5.05%
25.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 41.59
BIIB's Operating Margin % is ranked higher than
95% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. BIIB: 41.59 )
Ranked among companies with meaningful Operating Margin % only.
BIIB' s Operating Margin % Range Over the Past 10 Years
Min: 24.59  Med: 33.48 Max: 45.44
Current: 41.59
24.59
45.44
Net Margin % 30.17
BIIB's Net Margin % is ranked higher than
93% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. BIIB: 30.17 )
Ranked among companies with meaningful Net Margin % only.
BIIB' s Net Margin % Range Over the Past 10 Years
Min: 19.11  Med: 24.74 Max: 32.95
Current: 30.17
19.11
32.95
ROE % 30.27
BIIB's ROE % is ranked higher than
96% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. BIIB: 30.27 )
Ranked among companies with meaningful ROE % only.
BIIB' s ROE % Range Over the Past 10 Years
Min: 10.06  Med: 20.75 Max: 35.15
Current: 30.27
10.06
35.15
ROA % 16.05
BIIB's ROA % is ranked higher than
95% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. BIIB: 16.05 )
Ranked among companies with meaningful ROA % only.
BIIB' s ROA % Range Over the Past 10 Years
Min: 7.43  Med: 14.4 Max: 22.42
Current: 16.05
7.43
22.42
ROC (Joel Greenblatt) % 140.33
BIIB's ROC (Joel Greenblatt) % is ranked higher than
96% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. BIIB: 140.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 54.17  Med: 90.54 Max: 189.7
Current: 140.33
54.17
189.7
3-Year Revenue Growth Rate 21.60
BIIB's 3-Year Revenue Growth Rate is ranked higher than
73% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. BIIB: 21.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -15.1  Med: 21.6 Max: 78.2
Current: 21.6
-15.1
78.2
3-Year EBITDA Growth Rate 28.10
BIIB's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. BIIB: 28.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIIB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 25 Max: 127.9
Current: 28.1
0
127.9
3-Year EPS without NRI Growth Rate 29.40
BIIB's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. BIIB: 29.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66  Med: 34.9 Max: 205.2
Current: 29.4
-66
205.2
GuruFocus has detected 3 Warning Signs with Biogen Inc $BIIB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIIB's 10-Y Financials

Financials (Next Earnings Date: 2017-07-21 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

BIIB Guru Trades in Q2 2016

HOTCHKIS & WILEY 229,000 sh (New)
Sarah Ketterer 489,263 sh (New)
David Dreman 150 sh (New)
Paul Tudor Jones 18,123 sh (+1712.30%)
Andreas Halvorsen 3,210,507 sh (+1290.15%)
Richard Snow 211,561 sh (+130.46%)
Ray Dalio 51,461 sh (+122.72%)
Jeff Auxier 17,985 sh (+99.50%)
First Eagle Investment 332,760 sh (+48.17%)
Pioneer Investments 1,099 sh (+24.89%)
Joel Greenblatt 368,095 sh (+23.24%)
Ron Baron 19,621 sh (+22.27%)
Lee Ainslie 11,010 sh (+17.50%)
Ken Fisher 101,919 sh (+12.74%)
John Paulson 123,100 sh (+3.97%)
Vanguard Health Care Fund 3,956,663 sh (+3.85%)
John Buckingham 16,831 sh (+0.13%)
Ronald Muhlenkamp 3,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Murray Stahl 7,705 sh (unchged)
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Mario Gabelli 4,797 sh (-0.27%)
Ronald Muhlenkamp 23,703 sh (-0.63%)
PRIMECAP Management 16,024,861 sh (-1.37%)
Frank Sands 2,970,230 sh (-5.44%)
Jim Simons 40,400 sh (-68.35%)
Eaton Vance Worldwide Health Sciences Fund 176,000 sh (-12.00%)
» More
Q3 2016

BIIB Guru Trades in Q3 2016

Richard Pzena 642 sh (New)
Eric Mindich 64,000 sh (New)
Steven Cohen 117,548 sh (New)
George Soros 1,994 sh (New)
Paul Tudor Jones 125,668 sh (+593.42%)
Jim Simons 238,261 sh (+489.75%)
John Paulson 308,000 sh (+150.20%)
First Eagle Investment 457,260 sh (+37.41%)
HOTCHKIS & WILEY 306,100 sh (+33.67%)
Jeff Auxier 22,635 sh (+25.85%)
David Dreman 150 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Paul Tudor Jones 20,000 sh (unchged)
Murray Stahl 7,705 sh (unchged)
Ronald Muhlenkamp 23,478 sh (-0.95%)
John Buckingham 16,642 sh (-1.12%)
Ken Fisher 100,718 sh (-1.18%)
PRIMECAP Management 15,693,905 sh (-2.07%)
Richard Snow 203,525 sh (-3.80%)
Vanguard Health Care Fund 3,759,703 sh (-4.98%)
Lee Ainslie 10,380 sh (-5.72%)
Frank Sands 2,789,266 sh (-6.09%)
Sarah Ketterer 404,444 sh (-17.34%)
Andreas Halvorsen 2,186,336 sh (-31.90%)
Joel Greenblatt 245,468 sh (-33.31%)
Pioneer Investments 665 sh (-39.49%)
Mario Gabelli 1,897 sh (-60.45%)
Ron Baron 6,577 sh (-66.48%)
Ray Dalio 900 sh (-98.25%)
Eaton Vance Worldwide Health Sciences Fund 166,500 sh (-5.40%)
» More
Q4 2016

BIIB Guru Trades in Q4 2016

John Hussman 350 sh (New)
John Burbank 5,904 sh (New)
Eric Mindich 327,882 sh (+412.32%)
David Dreman 602 sh (+301.33%)
Jim Simons 707,495 sh (+196.94%)
Jeff Auxier 25,305 sh (+11.80%)
Lee Ainslie 10,880 sh (+4.82%)
Vanguard Health Care Fund 3,841,803 sh (+2.18%)
John Buckingham 16,934 sh (+1.75%)
Ken Fisher 101,887 sh (+1.16%)
Ron Baron 6,625 sh (+0.73%)
Ronald Muhlenkamp 3,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Eric Mindich 400,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 166,500 sh (unchged)
Pioneer Investments Sold Out
Richard Pzena Sold Out
Ray Dalio Sold Out
Sarah Ketterer Sold Out
George Soros Sold Out
PRIMECAP Management 15,584,387 sh (-0.70%)
Ronald Muhlenkamp 23,279 sh (-0.85%)
Mario Gabelli 1,872 sh (-1.32%)
Joel Greenblatt 240,311 sh (-2.10%)
Richard Snow 192,361 sh (-5.49%)
HOTCHKIS & WILEY 286,800 sh (-6.31%)
Frank Sands 2,578,909 sh (-7.54%)
Andreas Halvorsen 1,918,812 sh (-12.24%)
Murray Stahl 6,655 sh (-13.63%)
First Eagle Investment 257,025 sh (-43.79%)
Steven Cohen 53,542 sh (-54.45%)
John Paulson 52,200 sh (-83.05%)
Paul Tudor Jones 7,815 sh (-93.78%)
» More
Q1 2017

BIIB Guru Trades in Q1 2017

Manning & Napier Advisors, Inc 122,675 sh (New)
Ken Fisher 109,414 sh (+7.39%)
Spiros Segalas Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:SHPGF, OTCPK:CSLLY, NAS:REGN, NAS:TIG, NAS:GILD, OTCPK:NONOF, OTCPK:ALIOY, NAS:ALXN, NAS:INCY, NAS:VRTX, NAS:CELG, OTCPK:GIKLY, NAS:BMRN, OTCPK:UCBJY, OTCPK:NVZMF, OTCPK:GMXAY, NAS:SGEN, NAS:ALKS, NAS:JAZZ, NAS:TSRO » details
Traded in other countries:BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Headquarter Location:USA
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen markets novel MS drugs Tysabri and Tecfidera independently. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and is launching Spinraza with partner Ionis.

Top Ranked Articles about Biogen Inc

Spiros Segalas Sells American Tower, Biogen, Regeneron, Disney Guru's largest 1st-quarter trades
Spiros Segalas (Trades, Portfolio) manages the Harbor Capital Appreciation Fund. The portfolio is composed of 58 stocks with a total value of $24,593 million. During the first quarter, the guru sold shares in the following stocks: Read more...
Health Care Companies Showing Good Defensive Potential Deep analysis of historical financial trends for health care companies
Among U.S. companies, health care companies offer good defensive-investing opportunities. Such companies, including Johnson & Johnson (NYSE:JNJ), Biogen Inc. (NASDAQ:BIIB) and VCA Inc. (NASDAQ:WOOF), generally had strong financial strength and gross margins. Read more...
Sarah Ketterer Takes 3 Positions in 2nd Quarter Guru reports quarterly portfolio
Sarah Ketterer (Trades, Portfolio), founder and CEO of Causeway Capital Management LLC, creates long-term capital growth for her shareholders through value-oriented investing. As discussed in the fund’s prospectus, Ketterer prefers stocks that have low valuations and good financial strength. During the second quarter, the fund invested in three new companies, including major Chinese online media company Baidu Inc. (NASDAQ:BIDU). Read more...
Joel Greenblatt Bets on eBay, Intel, Biogen The investor's top buys in the 1st quarter
Joel Greenblatt (Trades, Portfolio) is founder and managing partner of Gotham Asset Management LLC. He is known for the invention of Magic Formula Investing and founded the New York Securities Auction Corporation (NYSAC). Read more...
Richard Snow Boosts Biogen, Keysight Technologies The largest increases by the guru during the 1st quarter
Richard Snow (Trades, Portfolio) is founder of Snow Capital. Snow began his career investing the proceeds from the sale of the Snow family businesses. During the first quarter he bought the following shares: Read more...

Ratios

vs
industry
vs
history
PE Ratio 17.46
BIIB's PE Ratio is ranked higher than
78% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. BIIB: 17.46 )
Ranked among companies with meaningful PE Ratio only.
BIIB' s PE Ratio Range Over the Past 10 Years
Min: 10.8  Med: 22.33 Max: 439.5
Current: 17.46
10.8
439.5
Forward PE Ratio 13.59
BIIB's Forward PE Ratio is ranked higher than
74% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. BIIB: 13.59 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.46
BIIB's PE Ratio without NRI is ranked higher than
76% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. BIIB: 17.46 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIIB' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.8  Med: 22.33 Max: 488.33
Current: 17.46
10.8
488.33
Price-to-Owner-Earnings 26.48
BIIB's Price-to-Owner-Earnings is ranked higher than
68% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. BIIB: 26.48 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BIIB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.96  Med: 22.34 Max: 155.47
Current: 26.48
9.96
155.47
PB Ratio 5.20
BIIB's PB Ratio is ranked lower than
56% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. BIIB: 5.20 )
Ranked among companies with meaningful PB Ratio only.
BIIB' s PB Ratio Range Over the Past 10 Years
Min: 1.71  Med: 4.04 Max: 8.84
Current: 5.2
1.71
8.84
PS Ratio 5.28
BIIB's PS Ratio is ranked higher than
72% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. BIIB: 5.28 )
Ranked among companies with meaningful PS Ratio only.
BIIB' s PS Ratio Range Over the Past 10 Years
Min: 2.59  Med: 5.46 Max: 11
Current: 5.28
2.59
11
Price-to-Free-Cash-Flow 29.21
BIIB's Price-to-Free-Cash-Flow is ranked higher than
72% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. BIIB: 29.21 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIIB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.36  Med: 19.3 Max: 36.19
Current: 29.21
9.36
36.19
Price-to-Operating-Cash-Flow 16.32
BIIB's Price-to-Operating-Cash-Flow is ranked higher than
76% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. BIIB: 16.32 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.32  Med: 16.21 Max: 32.51
Current: 16.32
7.32
32.51
EV-to-EBIT 12.86
BIIB's EV-to-EBIT is ranked higher than
71% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. BIIB: 12.86 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 15.7 Max: 62.7
Current: 12.86
7.5
62.7
EV-to-EBITDA 10.59
BIIB's EV-to-EBITDA is ranked higher than
70% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. BIIB: 10.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 12.3 Max: 24.9
Current: 10.59
6.1
24.9
PEG Ratio 0.61
BIIB's PEG Ratio is ranked higher than
89% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. BIIB: 0.61 )
Ranked among companies with meaningful PEG Ratio only.
BIIB' s PEG Ratio Range Over the Past 10 Years
Min: 0.32  Med: 0.84 Max: 35.41
Current: 0.61
0.32
35.41
Shiller PE Ratio 34.01
BIIB's Shiller PE Ratio is ranked higher than
68% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. BIIB: 34.01 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 29.54  Med: 77.52 Max: 4395
Current: 34.01
29.54
4395
Current Ratio 2.29
BIIB's Current Ratio is ranked lower than
66% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. BIIB: 2.29 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 4.16 Max: 20.41
Current: 2.29
0.78
20.41
Quick Ratio 1.98
BIIB's Quick Ratio is ranked lower than
67% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. BIIB: 1.98 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 3.94 Max: 20.41
Current: 1.98
0.7
20.41
Days Inventory 230.44
BIIB's Days Inventory is ranked lower than
78% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. BIIB: 230.44 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 219.47  Med: 238.11 Max: 266.3
Current: 230.44
219.47
266.3
Days Sales Outstanding 47.52
BIIB's Days Sales Outstanding is ranked higher than
64% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. BIIB: 47.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 45.32 Max: 48.62
Current: 47.52
39.79
48.62
Days Payable 74.49
BIIB's Days Payable is ranked higher than
55% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. BIIB: 74.49 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 69.07  Med: 98.14 Max: 148.21
Current: 74.49
69.07
148.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
BIIB's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. BIIB: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -92.1  Med: -0.3 Max: 30.9
Current: 3
-92.1
30.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 15.86
BIIB's Price-to-Tangible-Book is ranked lower than
84% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. BIIB: 15.86 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.07  Med: 4.85 Max: 24.7
Current: 15.86
0.07
24.7
Price-to-Intrinsic-Value-Projected-FCF 1.72
BIIB's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
73% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. BIIB: 1.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.05  Med: 1.71 Max: 12.73
Current: 1.72
0.05
12.73
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.61
BIIB's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
92% of the 24 Companies
in the Global Biotechnology industry.

( Industry Median: 1.21 vs. BIIB: 0.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.97
BIIB's Price-to-Median-PS-Value is ranked higher than
53% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BIIB: 0.97 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.91 Max: 7.11
Current: 0.97
0.05
7.11
Price-to-Peter-Lynch-Fair-Value 0.70
BIIB's Price-to-Peter-Lynch-Fair-Value is ranked higher than
91% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. BIIB: 0.70 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BIIB' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.41  Med: 1.2 Max: 18.88
Current: 0.7
0.41
18.88
Price-to-Graham-Number 3.51
BIIB's Price-to-Graham-Number is ranked lower than
57% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. BIIB: 3.51 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIIB' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.07  Med: 2.82 Max: 33.65
Current: 3.51
0.07
33.65
Earnings Yield (Greenblatt) % 7.77
BIIB's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. BIIB: 7.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 6.4 Max: 13.4
Current: 7.77
1.6
13.4
Forward Rate of Return (Yacktman) % 34.17
BIIB's Forward Rate of Return (Yacktman) % is ranked higher than
80% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. BIIB: 34.17 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -4.4  Med: 28.1 Max: 45.7
Current: 34.17
-4.4
45.7

More Statistics

Revenue (TTM) (Mil) $11,533
EPS (TTM) $ 15.97
Beta0.50
Short Percentage of Float1.22%
52-Week Range $205.43 - 307.33
Shares Outstanding (Mil)212.12

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 11,575 12,265 13,583
EPS ($) 20.62 22.13 23.78
EPS without NRI ($) 20.62 22.13 23.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.85%
Dividends per Share ($)
» More Articles for NAS:BIIB

Headlines

Articles On GuruFocus.com
Spiros Segalas Sells American Tower, Biogen, Regeneron, Disney Apr 21 2017 
Five Stocks I Like on the NASDAQ Market Mar 21 2017 
Jeff Auxier Invests in Gilead, Wells Fargo, Apple Mar 06 2017 
Weekly CEO Buys Highlights Mar 06 2017 
New Features: Individual Portfolio Tracker and Value Screens Tracker Mar 03 2017 
GuruFocus Interview: Orbimed Guru Sam Isaly on Investing in New Era of Healthcare Feb 15 2017 
8 Stocks Trading Below Peter Lynch Value Jan 23 2017 
7 Stocks for 2017 Jan 20 2017 
Steven Romick Spots Next Area of Interest, Health Care Jan 13 2017 
John Paulson Continues to Buy These 8 Stocks Dec 23 2016 

More From Other Websites
Biogen, Inc. :BIIB-US: Earnings Analysis: Q1, 2017 By the Numbers : April 27, 2017 Apr 27 2017
Biogen Still Dominated the Multiple Sclerosis Market in 1Q17 Apr 27 2017
Analysts’ Recommendations for Biogen in 1Q17 Apr 27 2017
Biogen Reports Strong Revenue Growth in 1Q17 Apr 27 2017
Biogen Inc. Earnings: New Drug Sparks Life Apr 26 2017
​Hyde Park boy with rare disease wins appeal, will receive Biogen drug Apr 26 2017
Stock Market News for April 26, 2017 Apr 26 2017
Edited Transcript of BIIB earnings conference call or presentation 25-Apr-17 12:30pm GMT Apr 26 2017
Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : April 26, 2017 Apr 26 2017
Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug Apr 26 2017
Today's Research Reports on Stocks to Watch: Lockheed Martin and Biogen Apr 26 2017
Better Buy: Amgen Inc. vs. Biogen Apr 26 2017
Spinraza's Fast Start Puts Ionis on a Path to Profit Apr 25 2017
Biogen Earnings Top As $125,000 Drug Starts Well Apr 25 2017
Biogen and Alzheimer’s: There’s a Fundamental Problem Here Apr 25 2017
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong Apr 25 2017
Biogen: Stuck in a Rut? Apr 25 2017
Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers Apr 25 2017
​Biogen shares jump as launch of new drug beats expectations Apr 25 2017
US STOCKS-Nasdaq breaches 6,000 mark for first time ever Apr 25 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)